APA (7th ed.) Citation

K, L., R, I., Y, L., J, Z., Z, C., J, W., . . . D, F. (2025). USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I. The Journal of clinical investigation, 136(1), . https://doi.org/10.1172/JCI193162

Chicago Style (17th ed.) Citation

K, Liu, et al. "USP22 Drives Tumor Immune Evasion and Checkpoint Blockade Resistance Through EZH2-mediated Epigenetic Silencing of MHC-I." The Journal of Clinical Investigation 136, no. 1 (2025). https://doi.org/10.1172/JCI193162.

MLA (9th ed.) Citation

K, Liu, et al. "USP22 Drives Tumor Immune Evasion and Checkpoint Blockade Resistance Through EZH2-mediated Epigenetic Silencing of MHC-I." The Journal of Clinical Investigation, vol. 136, no. 1, 2025, https://doi.org/10.1172/JCI193162.